Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 11/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.46 |
| ▸ | FLT1 | P17948 | 3/20 | 0.46 |
| ▸ | FLT4 | P35916 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29163338 | 0.93 | FGFR4 (0.58) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL25162437 | 0.86 | FGFR4 (0.72) | FGFR4FGFR1FGFR2FGFR3BTK | |
| SCHEMBL29163328 | 0.80 | FGFR4 (0.47) | FGFR4FGFR1FGFR2BTK | |
| SCHEMBL25162439 | 0.80 | FGFR4 (0.74) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL25162435 | 0.80 | FGFR4 (0.74) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL25162624 | 0.79 | FGFR4 (0.51) | FGFR4FGFR1FGFR2FGFR3FLT1 | |
| SCHEMBL30365929 | 0.76 | FGFR4 (0.70) | FGFR4FGFR1FGFR2FGFR3FLT1 | |
| SCHEMBL27428516 | 0.75 | FGFR4 (0.66) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL25162206 | 0.75 | FGFR4 (0.80) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL25162186 | 0.75 | FGFR4 (0.81) | FGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912602-A | 2-oxo-1, 2-dihydro-1, 6-naphthyridine-7-based compound and preparation method and application thereof | 温州医科大学 | 2022-01-11 | — | — | CN | disclosed |